Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for Sacituzumab Tirumotecan (MK-2870) in endometrial cancer after platinum therapy and prior immunotherapy; the study is active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Endometrial Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING